Patent intelligence · US
US 10646485
Process of making stable abuse-deterrent oral formulations
Process of making stable abuse-deterrent oral formulations
Patent details — US 10646485
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 12, 2020
- Expiration
- May 7, 2040
- Applicant
- Collegium Pharmaceutical, Inc.
- Claims
- 67
- CPC classes
- A61K, A61K31/485, A61K47/12, A61K47/26
Quick answer
US 10646485 (Process of making stable abuse-deterrent oral formulations) is held by Collegium Pharmaceutical, Inc.. Status: granted. Granted May 12, 2020. Expires May 7, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Collegium Pharmaceutical, Inc.
- Grant date
- Expiration
- Claims
- 67
- CPC classes
- A61K, A61K31/485, A61K47/12, A61K47/26, A61K47/44, A61K9/1617
More from Collegium Pharmaceutical, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11191758
Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
granted -
US 10668060
Tamper-resistant pharmaceutical compositions of opioids and other drugs
granted -
US 10525052
Abuse-deterrent drug formulations
granted -
US 10525053
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
granted -
US 10188644
Process of making stable abuse-deterrent oral formulations
granted -
US 10004729
Tamper-resistant pharmaceutical compositions of opioids and other drugs
granted -
US 9968598
Process of making stable abuse-deterrent oral formulations
granted
Frequently asked questions
What is US patent 10646485?
US 10646485 (Process of making stable abuse-deterrent oral formulations) is held by Collegium Pharmaceutical, Inc.. Status: granted. Granted May 12, 2020. Expires May 7, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10646485?
Collegium Pharmaceutical, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.
When does US 10646485 expire?
Our index shows an expiration date of May 7, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.